High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China

References

• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Portillo-Sanchez P, Bril F, Maximos M, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metabol. 2015;100(6):2231–2238.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–1554.
   PubMed Web of Science ®Google Scholar
• Younossi ZM. Non-alcoholic fatty liver disease – a global public health perspective. J Hepatol. 2019;70(3):531–544.
   PubMed Web of Science ®Google Scholar
• Sesti G, Sciacqua A, Fiorentino TV, et al. Association between noninvasive fibrosis markers and cardio-vascular organ damage among adults with hepatic steatosis. PloS One. 2014;9(8):e104941.
   PubMed Web of Science ®Google Scholar
• Schonmann Y, Yeshua H, Bentov I, et al. Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. Dig Liver Dis. 2021;53(1):79–85.
   PubMedGoogle Scholar
• Polak JF, Szklo M, Kronmal RA, et al. The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2013;2(2):e000087.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–2381.
   PubMed Web of Science ®Google Scholar
• Sinn DH, Cho SJ, Gu S, et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis. Gastroenterology. 2016;151(3):481–488.e481.
   PubMed Web of Science ®Google Scholar
• Kozakova M, Palombo C, Eng MP, Dekker J, Flyvbjerg A, Mitrakou A, Gastaldelli A, Ferrannini E. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology (Baltimore, Md) 2012;55(5):1406–1415.
   PubMed Web of Science ®Google Scholar
• Sunbul M, Agirbasli M, Durmus E, et al. Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis. 2014;237(2):490–493.
   PubMed Web of Science ®Google Scholar
• Lee HH, Cho Y, Choi YJ, et al. Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study. Cardiovasc Diabetol. 2020;19(1):81.
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu M, Wang T, et al. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease. Atherosclerosis. 2015;241(1):145–150.
   PubMed Web of Science ®Google Scholar
• Tan EC, Tai MS, Chan WK, et al. Association between non-alcoholic fatty liver disease evaluated by transient elastography with extracranial carotid atherosclerosis in a multiethnic Asian community. JGH Open. 2019;3(2):117–125.
   PubMed Web of Science ®Google Scholar
• Yu XY, Song XX, Tong YL, et al. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China. Medicine. 2020; 99(48):e23360.
   PubMed Web of Science ®Google Scholar
• Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness consensus (2004–2006). an update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007;23(1):75–80.
   PubMed Web of Science ®Google Scholar
• Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(23):7392–7402.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–1609.
   PubMed Web of Science ®Google Scholar
• Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (Baltimore, Md). 2007;45(4):846–854.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mantzoros C, Mikhailidis DP. Adiponectin, lipids and atherosclerosis. Curr Opin Lipidol. 2017;28(4):347–354.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr.et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–2752.
   PubMed Web of Science ®Google Scholar
• Wei JL, Leung JC, Loong TC, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using Proton-Magnetic resonance spectroscopy. Am J Gastroenterol. 2015;110(9):1306–1314. quiz 1315.
   PubMed Web of Science ®Google Scholar
• Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a Meta-analysis. J Hepatol. 2016; 65(3):589–600.
   PubMed Web of Science ®Google Scholar
• Bonci E, Chiesa C, Versacci P, et al. Association of nonalcoholic fatty liver disease with subclinical cardiovascular changes: a systematic review and meta-analysis. Biomed Res Int. 2015;2015:213737.
   PubMed Web of Science ®Google Scholar
• Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis. 2015;239(1):192–202.
   PubMed Web of Science ®Google Scholar
• Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–352.
   PubMed Web of Science ®Google Scholar
• Dam-Larsen S, Becker U, Franzmann M, et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol. 2009;44(10):1236–1243.
   PubMed Web of Science ®Google Scholar
• Ghouri N, Preiss D, Sattar NJH. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology. 2010;52(3):1156–1161.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–2219.
   PubMedGoogle Scholar
• Ma J, Hwang SJ, Pedley A, et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017;66(2):390–397.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang T, Zhang C, et al. Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population. BMJ Open. 2015;5(9):e008204.
   PubMed Web of Science ®Google Scholar
• Ciardullo S, Monti T, Sala I, et al. Nonalcoholic fatty liver disease and advanced fibrosis in US adults across blood pressure categories. Hypertension (Dallas, Tex: 1979). 2020;76(2):562–568.
   PubMed Web of Science ®Google Scholar
• Sorrentino P, Terracciano L, D’Angelo S, et al. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am J Gastroenterol. 2010;105(2):336–344.
   PubMed Web of Science ®Google Scholar
• Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and Meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–654.e641–649; quiz e639–640.
   PubMed Web of Science ®Google Scholar
• Arima S, Uto H, Ibusuki R, et al. Hypertension exacerbates liver injury and hepatic fibrosis induced by a choline-deficient L-amino acid-defined diet in rats. Int J Mol Med. 2014;33(1):68–76.
   PubMed Web of Science ®Google Scholar
• McEvoy JW, Blaha MJ, DeFilippis AP, et al. Cigarette smoking and cardiovascular events: role of inflammation and subclinical atherosclerosis from the MultiEthnic Study of Atherosclerosis. ATVB. 2015;35(3):700–709.
   Web of Science ®Google Scholar
• Zhu J, Nelson K, Toth J, et al. Nicotine dependence as an independent risk factor for atherosclerosis in the National Lung Screening Trial. BMC Public Health. 2019;19(1):103.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Katsiki N, Doumas M, et al. Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Curr Med Res Opin. 2013;29(10):1263–1274.
   PubMed Web of Science ®Google Scholar
• Harris B, Klein R, Jerosch-Herold M, et al. The association of systemic microvascular changes with lung function and lung density: a cross-sectional study. PloS One. 2012;7(12):e50224.
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu B, Zhu J, et al. Nicotine-mediated autophagy of vascular smooth muscle cell accelerates atherosclerosis via nAChRs/ROS/NF-κB signaling pathway. Atherosclerosis. 2019;284:1–10.
   PubMed Web of Science ®Google Scholar
• Tu SH, Chen MY, Chen LC, et al. Pu-erh tea extract attenuates nicotine-induced foam cell formation in primary cultured monocytes: an in vitro mechanistic study. J Agric Food Chem. 2016;64(16):3186–3195.
   PubMed Web of Science ®Google Scholar
• Cavero-Redondo I, Peleteiro B, Álvarez-Bueno C, et al. Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and Meta-analysis. BMJ Open. 2017;7(7):e015949.
   PubMed Web of Science ®Google Scholar
• Mukai N, Ninomiya T, Hata J, et al. Association of hemoglobin A1c and glycated albumin with carotid atherosclerosis in community-dwelling Japanese subjects: the Hisayama Study. Cardiovasc Diabetol. 2015;14(1):84.
   PubMed Web of Science ®Google Scholar
• Ma X, Shen Y, Hu X, et al. Associations of glycated haemoglobin A1c and glycated albumin with subclinical atherosclerosis in Middle-aged and elderly Chinese population with impaired glucose regulation. Clin Exp Pharmacol Physiol. 2015; 42(6):582–587.
   PubMed Web of Science ®Google Scholar
• Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168(15):1609–1616.
   PubMedGoogle Scholar
• Finelli C, Tarantino G. Is visceral fat reduction necessary to favour metabolic changes in the liver? J Gastrointestin Liver Dis. 2012;21(2):205–208.
   PubMed Web of Science ®Google Scholar
• Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142(4):711–725.e716.
   PubMed Web of Science ®Google Scholar
• Kim D, Kim WR. Nonobese fatty liver disease. Clin Gastroenterol Hepatol. 2017;15(4):474–485.
   PubMed Web of Science ®Google Scholar
• Blüher M. The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Curr Opin Lipidol. 2010;21(1):38–43.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59(6):1121–1140.
   PubMed Web of Science ®Google Scholar
• Saba L, Anzidei M, Sanfilippo R, et al. Imaging of the carotid artery. Atherosclerosis. 2012;220(2):294–309.
   PubMed Web of Science ®Google Scholar
• Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet (London, England). 2020;396(10250):565–582.
   PubMed Web of Science ®Google Scholar
• Man JJ, Beckman JA, Jaffe IZ. Sex as a biological variable in atherosclerosis. Circ Res. 2020;126(9):1297–1319.
   PubMed Web of Science ®Google Scholar